

Man-Fung Yuen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1430281/publications.pdf>

Version: 2024-02-01

498
papers

32,869
citations

4942

84
h-index

6113

159
g-index

528
all docs

528
docs citations

528
times ranked

23444
citing authors

#	ARTICLE	IF	CITATIONS
1	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	3.7	1,619
2	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	3.7	1,241
3	Viral hepatitis B. <i>Lancet, The</i> , 2003, 362, 2089-2094.	6.3	929
4	Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. <i>Hepatology International</i> , 2014, 8, 453-471.	1.9	861
5	Viral hepatitis C. <i>Lancet, The</i> , 2003, 362, 2095-2100.	6.3	758
6	Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). <i>Hepatology International</i> , 2009, 3, 269-282.	1.9	709
7	Lansoprazole for the Prevention of Recurrences of Ulcer Complications from Long-Term Low-Dose Aspirin Use. <i>New England Journal of Medicine</i> , 2002, 346, 2033-2038.	13.9	578
8	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. <i>Lancet Oncology, The</i> , 2011, 12, 568-574.	5.1	541
9	Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. <i>Journal of Hepatology</i> , 2009, 50, 80-88.	1.8	517
10	Hepatitis B virus infection. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18035.	18.1	490
11	Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. <i>Hepatology International</i> , 2019, 13, 353-390.	1.9	483
12	Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. <i>Hepatology</i> , 2000, 31, 330-335.	3.6	408
13	Hepatocellular carcinoma in the Asia pacific region. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 346-353.	1.4	407
14	Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. <i>Gut and Liver</i> , 2016, 10, 332-9.	1.4	399
15	HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 135, 1192-1199.	0.6	370
16	Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. <i>Hepatology</i> , 2001, 34, 785-791.	3.6	354
17	Chronic hepatitis B virus infection. <i>Lancet, The</i> , 2018, 392, 2313-2324.	6.3	351
18	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	343

#	ARTICLE	IF	CITATIONS
19	A global scientific strategy to cure hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 545-558.	3.7	342
20	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019, 71, 397-408.	1.8	341
21	Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. <i>Gut</i> , 2005, 54, 1610-1614.	6.1	317
22	Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3736-3743.	0.8	283
23	Promoter methylation of E-cadherin gene in gastric mucosa associated with <i>Helicobacter pylori</i> infection and in gastric cancer. <i>Gut</i> , 2003, 52, 502-506.	6.1	263
24	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 396-415.	3.7	237
25	Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. <i>Hepatology</i> , 2000, 31, 201-206.	3.6	230
26	Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease. <i>Antiviral Therapy</i> , 2007, 12, 1295-1304.	0.6	230
27	A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. <i>Cancer</i> , 2002, 94, 1747-1752.	2.0	222
28	HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects. <i>Hepatology</i> , 2004, 39, 1694-1701.	3.6	222
29	Long-term follow-up of interferon alfa treatment in chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. <i>Hepatology</i> , 2001, 34, 139-145.	3.6	207
30	Natural history of hepatitis-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2008, 14, 1652.	1.4	203
31	Entecavir Monotherapy Is Effective in Suppressing Hepatitis B Virus After Liver Transplantation. <i>Gastroenterology</i> , 2011, 141, 1212-1219.	0.6	190
32	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. <i>Gut</i> , 2015, 64, 667-672.	6.1	185
33	Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. <i>Hepatology</i> , 2013, 57, 399-408.	3.6	183
34	Recurrence of Hepatitis B-Related Hepatocellular Carcinoma Is Associated With High Viral Load at the Time of Resection. <i>American Journal of Gastroenterology</i> , 2008, 103, 1663-1673.	0.2	175
35	Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2715-2725.	1.3	168
36	The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points. <i>Annals of Internal Medicine</i> , 2007, 147, 58.	2.0	163

#	ARTICLE	IF	CITATIONS
37	Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. <i>Hepatology</i> , 2009, 49, 72-79.	3.6	163
38	Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2019, 156, 635-646.e9.	0.6	162
39	Review article: hepatitis B core-related antigen (<sc>HB</sc>crAg): an emerging marker for chronic hepatitis B virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 43-54.	1.9	161
40	Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 262-279.	1.8	160
41	A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. <i>Hepatology</i> , 2002, 36, 687-691.	3.6	157
42	Eradication of <i>Helicobacter pylori</i> infection reverses E-cadherin promoter hypermethylation. <i>Gut</i> , 2006, 55, 463-468.	6.1	157
43	Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. <i>Gut</i> , 2007, 57, 98-102.	6.1	154
44	Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. <i>Hepatology</i> , 2003, 37, 562-567.	3.6	146
45	Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety. <i>American Journal of Gastroenterology</i> , 2011, 106, 1264-1271.	0.2	145
46	Treatment of chronic hepatitis B: Evolution over two decades. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 138-143.	1.4	143
47	Hepatitis B Virus Core-Related Antigens as Markers for Monitoring Chronic Hepatitis B Infection. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3942-3947.	1.8	139
48	Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. <i>Hepatology</i> , 2011, 54, 829-836.	3.6	135
49	Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. <i>Liver International</i> , 2017, 37, 995-1001.	1.9	132
50	Expression of c-Myc, c-Fos, and c-Jun in hepatocellular carcinoma. <i>Cancer</i> , 2001, 91, 106-112.	2.0	127
51	Clinicopathological and prognostic significance of serum and tissue<sc>Dickkopf1</sc> levels in human hepatocellular carcinoma. <i>Liver International</i> , 2011, 31, 1494-1504.	1.9	127
52	Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. <i>Cancer Research</i> , 2003, 63, 7724-32.	0.4	127
53	Molecular Characterization of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus in Paid Blood Donors and Injection Drug Users in China. <i>Journal of Virology</i> , 2004, 78, 13591-13599.	1.5	126
54	Prevalence of Colorectal Neoplasm Among Patients With Newly Diagnosed Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 1412.	3.8	126

#	ARTICLE	IF	CITATIONS
55	Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, 275-281.	1.8	126
56	Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2006, 45, 646-653.	1.8	124
57	Hepatitis B and C virus-related carcinogenesis. <i>Clinical Microbiology and Infection</i> , 2009, 15, 964-970.	2.8	123
58	Liver Transplantation in Asian Patients With Chronic Hepatitis B Using Lamivudine Prophylaxis. <i>Annals of Surgery</i> , 2001, 233, 276-281.	2.1	122
59	Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1004-1010.e1.	2.4	122
60	Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. <i>Hepatology</i> , 2004, 40, 727-737.	3.6	119
61	Serological markers of liver cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2005, 19, 91-99.	1.0	118
62	Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. <i>Antiviral Research</i> , 2015, 121, 97-108.	1.9	116
63	Berberine and Coptidis Rhizoma as potential anticancer agents: Recent updates and future perspectives. <i>Journal of Ethnopharmacology</i> , 2015, 176, 35-48.	2.0	115
64	Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. <i>Gastroenterology</i> , 2019, 156, 1392-1403.e7.	0.6	115
65	Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance. <i>Journal of Hepatology</i> , 2020, 73, 952-964.	1.8	115
66	Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 553-560.	1.9	113
67	A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. <i>Gut</i> , 2003, 52, 416-419.	6.1	113
68	Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. <i>Hepatology</i> , 2007, 46, 1695-1703.	3.6	111
69	Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. <i>Clinical Microbiology and Infection</i> , 2014, 20, 1173-1180.	2.8	110
70	Oral Nucleoside/Nucleotide Analogs Without Hepatitis B Immune Globulin After Liver Transplantation for Hepatitis B. <i>American Journal of Gastroenterology</i> , 2013, 108, 942-948.	0.2	108
71	Chronic Hepatitis B "New Goals, New Treatment. <i>New England Journal of Medicine</i> , 2008, 359, 2488-2491.	13.9	107
72	Hepatoprotective Effects of Chinese Medicinal Herbs: A Focus on Anti-Inflammatory and Anti-Oxidative Activities. <i>International Journal of Molecular Sciences</i> , 2016, 17, 465.	1.8	107

#	ARTICLE	IF	CITATIONS
73	Molecular Tracing of the Global Hepatitis C Virus Epidemic Predicts Regional Patterns of Hepatocellular Carcinoma Mortality. <i>Gastroenterology</i> , 2006, 130, 703-714.	0.6	106
74	Activation of the caspase-8/Bid and Bax pathways in aspirin-induced apoptosis in gastric cancer. <i>Carcinogenesis</i> , 2005, 26, 541-546.	1.3	103
75	Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1179-1186.	1.9	103
76	PIN1 overexpression and β -catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. <i>Oncogene</i> , 2004, 23, 4182-4186.	2.6	101
77	Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. <i>Gut</i> , 2002, 51, 502-506.	6.1	98
78	A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. <i>Hepatology</i> , 2004, 40, 719-726.	3.6	96
79	18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 941-945.	2.4	94
80	<i>Helicobacter pylori</i> induces promoter methylation of E-cadherin via interleukin-1 β activation of nitric oxide production in gastric cancer cells. <i>Cancer</i> , 2012, 118, 4969-4980.	2.0	93
81	Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e125.	1.3	93
82	One-Year Entecavir or Lamivudine Therapy Results in Reduction of Hepatitis B Virus Intrahepatic Covalently Closed Circular DNA Levels. <i>Antiviral Therapy</i> , 2006, 11, 909-916.	0.6	93
83	Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. <i>Carcinogenesis</i> , 2004, 25, 1593-1598.	1.3	92
84	Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years. <i>Hepatology</i> , 2017, 66, 1036-1044.	3.6	89
85	Treatment of chronic hepatitis B. <i>Lancet Infectious Diseases</i> , The, 2001, 1, 232-241.	4.6	88
86	Long-term prospective follow-up of endoscopic oesophagitis in southern Chinese - prevalence and spectrum of the disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 2037-2042.	1.9	88
87	Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. <i>Hepatology</i> , 2013, 58, 923-931.	3.6	88
88	Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 575-583.e2.	2.4	86
89	Mannose-binding lectin in chronic hepatitis B virus infection. <i>Hepatology</i> , 2005, 42, 1037-1045.	3.6	85
90	Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 152-166.	3.7	85

#	ARTICLE	IF	CITATIONS
91	Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2006, 45, 553-559.	1.8	84
92	Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 97-104.	1.0	84
93	RNA Interference Therapy With ARCA520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020, 72, 19-31.	3.6	84
94	Transmissibility of Hepatitis B Virus (HBV) Infection through Blood Transfusion from Blood Donors with Occult HBV Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 624-632.	2.9	83
95	Association of Hepatitis B Virus Pre-S Deletions with the Development of Hepatocellular Carcinoma in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2011, 203, 646-654.	1.9	82
96	A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. <i>Hepatology</i> , 2012, 56, 812-819.	3.6	82
97	Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, 800-806.	1.8	82
98	Trends in the prevalence of peptic ulcer disease and <i>Helicobacter pylori</i> infection in family physician-referred uninvestigated dyspeptic patients in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 243-249.	1.9	81
99	Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. <i>Hepatology</i> , 2017, 65, 1451-1461.	3.6	81
100	Chronic Hepatitis C Virus Genotype 6 Infection: Response to Pegylated Interferon and Ribavirin. <i>Journal of Infectious Diseases</i> , 2008, 198, 808-812.	1.9	80
101	Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. <i>Gastroenterology</i> , 2005, 128, 361-375.	0.6	79
102	Nonalcoholic fatty liver disease in Asia: emerging perspectives. <i>Journal of Gastroenterology</i> , 2017, 52, 164-174.	2.3	79
103	Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. <i>Antiviral Therapy</i> , 2007, 12, 1295-303.	0.6	78
104	Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. <i>Liver International</i> , 2008, 28, 1408-1416.	1.9	77
105	Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 428-434.	1.4	77
106	Relationship between the Development of Precore and Core Promoter Mutations and Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B Virus. <i>Journal of Infectious Diseases</i> , 2002, 186, 1335-1338.	1.9	76
107	The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2005, 12, 373-379.	1.0	76
108	Safety, tolerability and antiviral activity of the antisense oligonucleotide bepiroviren in patients with chronic hepatitis B: a phase 2 randomized controlled trial. <i>Nature Medicine</i> , 2021, 27, 1725-1734.	15.2	76

#	ARTICLE	IF	CITATIONS
109	Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. <i>Hepatology</i> , 1999, 29, 1248-1251.	3.6	75
110	Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 573-583.	1.9	75
111	Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: Final report. <i>Vaccine</i> , 2008, 26, 6587-6591.	1.7	74
112	T1653 Mutation in the Box a Increases the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Genotype C Infection. <i>Clinical Infectious Diseases</i> , 2006, 42, 1-7.	2.9	73
113	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2020, 115, 271-280.	0.2	72
114	High Hepatitis B Surface Antigen Levels Predict Insignificant Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e43087.	1.1	71
115	A New Model Using Routinely Available Clinical Parameters to Predict Significant Liver Fibrosis in Chronic Hepatitis B. <i>PLoS ONE</i> , 2011, 6, e23077.	1.1	69
116	Does the Addition of Endoscopic Sphincterotomy to Stent Insertion Improve Drainage of the Bile Duct in Acute Suppurative Cholangitis?. <i>Gastrointestinal Endoscopy</i> , 2003, 58, 500-504.	0.5	68
117	The Duration of Lamivudine Therapy for Chronic Hepatitis B: Cessation vs. Continuation of Treatment After HBeAg Seroconversion. <i>American Journal of Gastroenterology</i> , 2009, 104, 1940-1946.	0.2	68
118	Retained common bile duct stones: a comparison between biliary stenting and complete clearance of stones by electrohydraulic lithotripsy. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 289-296.	1.9	67
119	Prevention of hepatocellular carcinoma in hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1352-1357.	1.4	67
120	Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. <i>Gut</i> , 2014, 63, 996-1004.	6.1	67
121	High prevalence of non-alcoholic fatty liver disease in the Chinese " results from the Hong Kong liver health census. <i>Liver International</i> , 2015, 35, 542-549.	1.9	67
122	Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives. <i>World Journal of Gastroenterology</i> , 2013, 19, 1890.	1.4	67
123	Hepatitis B Virus Genotypes B and C Do Not Affect the Antiviral Response to Lamivudine. <i>Antiviral Therapy</i> , 2003, 8, 531-534.	0.6	67
124	Twelve-year follow-up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. <i>Hepatology</i> , 1999, 29, 924-927.	3.6	66
125	Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 955-961.	1.4	65
126	Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. <i>Gut</i> , 2010, 59, 1389-1393.	6.1	65

#	ARTICLE	IF	CITATIONS
127	A Large Population Histology Study Showing the Lack of Association between ALT Elevation and Significant Fibrosis in Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e32622.	1.1	65
128	Does withholding aspirin for one week reduce the risk of post-sphincterotomy bleeding?. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 929-936.	1.9	64
129	Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. <i>Journal of Hepatology</i> , 2004, 41, 119-125.	1.8	64
130	Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). <i>Gastroenterology</i> , 2022, 162, 757-771.e4.	0.6	63
131	Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatitis B After 2 Years of Entecavir Treatment. <i>American Journal of Gastroenterology</i> , 2011, 106, 1766-1773.	0.2	62
132	Acute-on-chronic liver failure in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 662-669.	1.4	62
133	Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. <i>Journal of Viral Hepatitis</i> , 2017, 24, 654-661.	1.0	62
134	Antisense Targeting Protein Kinase C α and β 1 Inhibits Gastric Carcinogenesis. <i>Cancer Research</i> , 2004, 64, 5787-5794.	0.4	61
135	Review article: long-term safety of oral antiviral treatment for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 730-737.	1.9	60
136	Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 54-64.e1.	2.4	59
137	Lysyl Oxidase-Like 4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis. <i>Hepatology</i> , 2021, 73, 2326-2341.	3.6	59
138	Interferon and Ribavirin Therapy for Chronic Hepatitis C Virus Genotype 6: A Comparison with Genotype 1. <i>Journal of Infectious Diseases</i> , 2003, 187, 1071-1074.	1.9	58
139	HLA-DP and IL28B Polymorphisms: Influence of Host Genome on Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2013, 56, 1695-1703.	2.9	58
140	Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. <i>Molecular Biology Reports</i> , 2014, 41, 2989-2997.	1.0	58
141	Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1028-1034.	1.4	58
142	Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy. <i>American Journal of Gastroenterology</i> , 2016, 111, 1788-1795.	0.2	58
143	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 389-399.	1.9	58
144	Natural history of chronic hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, E20-E24.	1.4	57

#	ARTICLE	IF	CITATIONS
145	Transforming Growth Factor-Beta 1, Activin and Follistatin in Patients with Hepatocellular Carcinoma and Patients with Alcoholic Cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 233-238.	0.6	56
146	Outcome of emergency ERCP for acute cholangitis in patients 90 years of age and older. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 1153-1158.	1.9	56
147	Two subtypes (subgenotypes) of hepatitis B virus genotype C: A novel subtyping assay based on restriction fragment length polymorphism. <i>Hepatology Research</i> , 2005, 33, 216-24.	1.8	56
148	Genome-Wide Association Study of Hepatocellular Carcinoma in Southern Chinese Patients with Chronic Hepatitis B Virus Infection. <i>PLoS ONE</i> , 2011, 6, e28798.	1.1	56
149	Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. <i>Journal of Hepatology</i> , 2003, 39, 850-855.	1.8	55
150	Role of hepatitis B core protein in HBV transcription and recruitment of histone acetyltransferases to cccDNA minichromosome. <i>Antiviral Research</i> , 2017, 144, 1-7.	1.9	54
151	Systemic inflammatory response syndrome in acute-on-chronic liver failure: Relevance of "golden window": A prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1989-1997.	1.4	53
152	Acute cholangitis-predictive factors for emergency ERCP. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1633-1637.	1.9	52
153	Evaluation of an automated immunochemical fecal occult blood test for colorectal neoplasia detection in a Chinese population. <i>Cancer</i> , 2003, 97, 2420-2424.	2.0	52
154	Cyclooxygenase-2 inhibitor (SC-236) suppresses activator protein-1 through c-Jun NH2-terminal kinase. <i>Gastroenterology</i> , 2004, 126, 136-147.	0.6	52
155	Correlation of Liver Stiffness and Histological Features in Healthy Persons and in Patients With Occult Hepatitis B, Chronic Active Hepatitis B, or Hepatitis B Cirrhosis. <i>American Journal of Gastroenterology</i> , 2010, 105, 1116-1122.	0.2	52
156	Mild-to-Moderate Elevation of Alanine Aminotransferase Increases Liver Stiffness Measurement by Transient Elastography in Patients With Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2011, 106, 492-496.	0.2	52
157	Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. <i>Journal of Hepatology</i> , 2013, 59, 709-716.	1.8	52
158	Estradiol induces apoptosis via activation of miRNA-23a and p53: implication for gender difference in liver cancer development. <i>Oncotarget</i> , 2015, 6, 34941-34952.	0.8	52
159	Significance of HBV DNA Levels in Liver Histology of HBeAg and Anti-HBe Positive Patients with Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2004, 99, 2032-2037.	0.2	51
160	Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer. <i>Cancer</i> , 2009, 115, 5441-5449.	2.0	51
161	Nidogen 1-enriched Extracellular Vesicles Facilitate Extrahepatic Metastasis of Liver Cancer by Activating Pulmonary Fibroblasts to Secrete Tumor Necrosis Factor Receptor 1. <i>Advanced Science</i> , 2020, 7, 2002157.	5.6	50
162	HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy. <i>Hepatology</i> , 2021, 73, 2167-2179.	3.6	50

#	ARTICLE	IF	CITATIONS
163	Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. <i>Gut</i> , 2021, 70, 775-783.	6.1	50
164	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e784-e793.	2.4	49
165	Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e116.	1.3	48
166	Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B antigen seroclearance. <i>Hepatology</i> , 2018, 68, 462-472.	3.6	48
167	Mirtazapine-Induced Hepatotoxicity. <i>Journal of Clinical Gastroenterology</i> , 2002, 35, 270-271.	1.1	47
168	Hepatitis B virus genotype A and D and clinical outcomes of liver transplantation for HBV-related disease. <i>Liver Transplantation</i> , 2004, 10, 58-64.	1.3	47
169	Prevalence of Fibrosis and Cirrhosis in Chronic Hepatitis B: Implications for Treatment and Management. <i>American Journal of Gastroenterology</i> , 2008, 103, 1421-1426.	0.2	47
170	Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. <i>Hepatology International</i> , 2010, 4, 386-395.	1.9	47
171	Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. <i>Journal of Viral Hepatitis</i> , 2011, 18, e200-5.	1.0	47
172	Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2017, 1860, 491-501.	0.9	47
173	Among Patients with Undetectable Hepatitis B Surface Antigen and Hepatocellular Carcinoma, a High Proportion Has Integration of HBV DNA into Hepatocyte DNA and No Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 449-456.	2.4	47
174	Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: Results from a multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 526-532.	1.8	46
175	Drug-Induced Acute-on-Chronic Liver Failure in Asian Patients. <i>American Journal of Gastroenterology</i> , 2019, 114, 929-937.	0.2	46
176	Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. <i>The Lancet Global Health</i> , 2022, 10, e278-e287.	2.9	46
177	Profound suppression of hepatitis B virus replication with lamivudine. <i>Journal of Medical Virology</i> , 2000, 61, 367-373.	2.5	45
178	Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. <i>Annals of Oncology</i> , 2003, 14, 1463-1467.	0.6	45
179	Prognostic Factors in Severe Exacerbation of Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2003, 36, 979-984.	2.9	44
180	Modulation of gut microbiota mediates berberine-induced expansion of immunosuppressive cells to against alcoholic liver disease. <i>Clinical and Translational Medicine</i> , 2020, 10, e112.	1.7	43

#	ARTICLE	IF	CITATIONS
181	APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 833-851.	1.9	43
182	Transarterial Chemoembolization for Inoperable, Early Stage Hepatocellular Carcinoma in Patients With Child-Pugh Grade A and B: Results of A Comparative Study in 96 Chinese Patients. <i>American Journal of Gastroenterology</i> , 2003, 98, 1181-1185.	0.2	42
183	Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin. <i>Cancer</i> , 2005, 104, 740-746.	2.0	42
184	Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2011, 18, 738-744.	1.0	42
185	Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 286-294.	1.1	42
186	Role of HLA-DP Polymorphisms on Chronicity and Disease Activity of Hepatitis B Infection in Southern Chinese. <i>PLoS ONE</i> , 2013, 8, e66920.	1.1	42
187	All-Trans Retinoic Acid Induces XAF1 Expression Through an Interferon Regulatory Factor-1 Element in Colon Cancer. <i>Gastroenterology</i> , 2006, 130, 747-758.	0.6	41
188	Polymorphisms of type I interferon receptor 1 promoter and their effects on chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2007, 46, 198-205.	1.8	41
189	Up-regulation of microRNAs, miR21 and miR23a in human liver cancer cells treated with <i>Coptidis rhizoma</i> aqueous extract. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 27-32.	0.8	41
190	Hepatocellular carcinoma: recent advances and emerging medical therapies. <i>F1000Research</i> , 2020, 9, 620.	0.8	41
191	New Susceptibility and Resistance HLA-DP Alleles to HBV-Related Diseases Identified by a Trans-Ethnic Association Study in Asia. <i>PLoS ONE</i> , 2014, 9, e86449.	1.1	40
192	Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia-Pacific region. <i>Hepatology International</i> , 2019, 13, 695-705.	1.9	40
193	Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. <i>Journal of Viral Hepatitis</i> , 2019, 26, 818-827.	1.0	40
194	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 224, 1890-1899.	1.9	40
195	Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 723-732.	3.7	40
196	Adefovir Dipivoxil Monotherapy and Combination Therapy with Lamivudine for the Treatment of Chronic Hepatitis B in an Asian Population. <i>Antiviral Therapy</i> , 2007, 12, 41-46.	0.6	40
197	A Randomized Placebo-Controlled, Dose-Finding Study of Oral Lb80380 in Hbeag-Positive Patients with Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 977-984.	0.6	40
198	Effect of Lamivudine Therapy on the Serum Covalently Closed-Circular (ccc) DNA of Chronic Hepatitis B Infection. <i>American Journal of Gastroenterology</i> , 2005, 100, 1099-1103.	0.2	39

#	ARTICLE	IF	CITATIONS
199	Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. <i>Hepatology</i> , 2010, 51, 767-776.	3.6	39
200	Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. <i>Gut</i> , 2016, 65, 887-888.	6.1	39
201	Epidemiology and natural history of Wilson's disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016. <i>World Journal of Gastroenterology</i> , 2017, 23, 7716-7726.	1.4	39
202	This is hepatitis—it is closer than you think. <i>Indian Journal of Medical Research</i> , 2012, 136, 3-6.	0.4	39
203	Psychometrics of the chronic liver disease questionnaire for Southern Chinese patients with chronic hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2009, 15, 3288.	1.4	38
204	Defining Normal Liver Stiffness Range in a Normal Healthy Chinese Population without Liver Disease. <i>PLoS ONE</i> , 2013, 8, e85067.	1.1	38
205	Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 7958.	1.6	38
206	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. <i>Hepatology International</i> , 2020, 14, 1023-1033.	1.9	38
207	A randomised controlled trial of endoscopic sphincterotomy in acute cholangitis without common bile duct stones. <i>Gut</i> , 2002, 51, 245-247.	6.1	37
208	Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation. <i>Clinical Infectious Diseases</i> , 2003, 37, 593-597.	2.9	37
209	Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. <i>Hepatology International</i> , 2020, 14, 35-46.	1.9	37
210	Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". <i>Journal of Hepatology</i> , 2020, 73, 1573-1574.	1.8	37
211	Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion. <i>Journal of Viral Hepatitis</i> , 2007, 14, 269-275.	1.0	36
212	Prevention and management of drug resistance for antihepatitis B treatment. <i>Lancet Infectious Diseases</i> , 2009, 9, 256-264.	4.6	36
213	East Asia expert opinion on treatment initiation for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1540-1550.	1.9	36
214	Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. <i>World Journal of Gastroenterology</i> , 2013, 19, 8887.	1.4	36
215	Real-Time PCR Assay Using Molecular Beacon for Quantitation of Hepatitis B Virus DNA. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3438-3440.	1.8	35
216	Natural history of chronic hepatitis C: Genotype 1 versus genotype 6. <i>Journal of Hepatology</i> , 2010, 53, 444-448.	1.8	35

#	ARTICLE	IF	CITATIONS
217	Deregulation of E-cadherin-catenin complex in precancerous lesions of gastric adenocarcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 534-539.	1.4	34
218	Effects of Primary Metronidazole and Clarithromycin Resistance to <i>Helicobacter pylori</i> on Omeprazole, Metronidazole, and Clarithromycin Triple-Therapy Regimen in a Region with High Rates of Metronidazole Resistance. <i>Clinical Infectious Diseases</i> , 2003, 37, 882-889.	2.9	34
219	Longitudinal Study of Hepatitis Activity and Viral Replication before and after HBeAg Seroconversion in Chronic Hepatitis B Patients Infected with Genotypes B and C. <i>Journal of Clinical Microbiology</i> , 2004, 42, 5036-5040.	1.8	34
220	Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 377-382.	1.9	34
221	Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. <i>Hepatology International</i> , 2013, 7, 98-105.	1.9	34
222	Hepatitis B core protein as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 1153-1159.	1.5	34
223	New Biomarkers of Chronic Hepatitis B. <i>Gut and Liver</i> , 2019, 13, 589-595.	1.4	34
224	Response to Combined Interferon and Ribavirin Is Better in Patients Infected with Hepatitis C Virus Genotype 6 than Genotype 1 in Hong Kong. <i>Intervirology</i> , 2006, 49, 96-98.	1.2	33
225	Revisiting the natural history of chronic hepatitis B: Impact of new concepts on clinical management. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 973-976.	1.4	33
226	Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. <i>Journal of Hepatology</i> , 2011, 55, 522-528.	1.8	33
227	Body mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1071-1079.	1.9	33
228	A Territorywide Prevalence Study on Blood-Borne and Enteric Viral Hepatitis in Hong Kong. <i>Journal of Infectious Diseases</i> , 2019, 219, 1924-1933.	1.9	32
229	Nucleic Acid-Based Cross-Linking Assay for Detection and Quantification of Hepatitis B Virus DNA. <i>Journal of Clinical Microbiology</i> , 1999, 37, 161-164.	1.8	32
230	Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 76, 883-895.	1.8	32
231	RNA interference as a novel treatment strategy for chronic hepatitis B infection. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 408-424.	4.5	32
232	Low Molecular Weight Heparin-Induced Liver Toxicity. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 691-694.	1.0	31
233	Five-lipoxygenase-activating protein inhibitor MK-886 induces apoptosis in gastric cancer through upregulation of p27kip1 and bax. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 31-37.	1.4	31
234	Coexistence between colorectal cancer/adenoma and coronary artery disease: results from 1382 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 535-539.	1.9	31

#	ARTICLE	IF	CITATIONS
235	Hbsag seroclearance in the natural history of chronic hepatitis b infection. <i>Current Hepatitis Reports</i> , 2006, 5, 23-26.	0.3	31
236	Editorial. <i>Journal of Viral Hepatitis</i> , 2007, 14, 599-599.	1.0	31
237	Mechanism of Entecavir Resistance of Hepatitis B Virus with Viral Breakthrough as Determined by Long-Term Clinical Assessment and Molecular Docking Simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 882-889.	1.4	31
238	Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. <i>Journal of Gastroenterology</i> , 2021, 56, 479-488.	2.3	31
239	Real-time quantification of hepatitis B virus core-promoter and pre-core mutants during hepatitis E antigen seroconversion. <i>Journal of Hepatology</i> , 2004, 40, 1008-1017.	1.8	30
240	Rare inborn errors associated with chronic hepatitis B virus infection*. <i>Hepatology</i> , 2012, 56, 1661-1670.	3.6	30
241	Use of Liver Stiffness Measurement for Liver Resection Surgery: Correlation with Indocyanine Green Clearance Testing and Post-Operative Outcome. <i>PLoS ONE</i> , 2013, 8, e72306.	1.1	30
242	Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 501-509.	1.9	30
243	Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment. <i>Journal of Hepatology</i> , 2020, 73, S20.	1.8	30
244	Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1959-1965.	1.9	29
245	Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B. <i>Hepatology International</i> , 2010, 4, 716-722.	1.9	29
246	Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy. <i>Journal of Hepatology</i> , 2011, 54, 195-200.	1.8	29
247	GS-12-Ascending dose cohort study of inarigivir - A novel RIG I agonist in chronic HBV patients: Final results of the ACHIEVE trial. <i>Journal of Hepatology</i> , 2019, 70, e47-e48.	1.8	29
248	Novel developments of hepatitis B: treatment goals, agents and monitoring tools. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 109-120.	1.3	29
249	Rebound of HBV DNA after cessation of nucleos(t)ide analogues in chronic hepatitis B patients with undetectable covalently closed circular DNA. <i>JHEP Reports</i> , 2020, 2, 100112.	2.6	29
250	<i>Wisteria floribunda</i> agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment. <i>Oncotarget</i> , 2017, 8, 47507-47517.	0.8	29
251	Validated questionnaire on diagnosis and symptom severity for functional constipation in the Chinese population. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 483-488.	1.9	28
252	Inhibition of human telomerase reverse transcriptase by nonsteroidal antiinflammatory drugs in colon carcinoma. <i>Cancer</i> , 2006, 106, 1243-1249.	2.0	28

#	ARTICLE	IF	CITATIONS
253	Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. <i>Journal of Gastroenterology</i> , 2016, 51, 487-495.	2.3	28
254	Evolution of Primary and Compensatory Lamivudine Resistance Mutations in Chronic Hepatitis B Virus-Infected Patients during Long-Term Lamivudine Treatment, Assessed by a Line Probe Assay. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3935-3941.	1.8	27
255	Regulation of XAF1 expression in human colon cancer cell by interferon $\hat{1}^2$: Activation by the transcription regulator STAT1. <i>Cancer Letters</i> , 2008, 260, 62-71.	3.2	27
256	Gastroesophageal Reflux Disease. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, e1-e7.	1.1	27
257	PS-080-Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold. <i>Journal of Hepatology</i> , 2019, 70, e51-e52.	1.8	27
258	Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00236.	1.3	27
259	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 46-60.e8.	2.4	27
260	Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, 2089-2097.	4.3	27
261	One-week ranitidine bismuth citrate-based triple therapy for the eradication of <i>Helicobacter pylori</i> in Hong Kong with high prevalence of metronidazole resistance. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 403-409.	1.9	26
262	Acute pancreatitis complicating acute exacerbation of chronic hepatitis B infection carries a poor prognosis. <i>Journal of Viral Hepatitis</i> , 2001, 8, 459-464.	1.0	26
263	Update on Clarithromycin Resistance in <i>Helicobacter pylori</i> in Hong Kong and Its Effect on Clarithromycin-Based Triple Therapy. <i>Digestion</i> , 2006, 73, 101-106.	1.2	26
264	Interleukin- $\hat{1}^2$ increases the risk of gastric cancer through induction of aberrant DNA methylation in a mouse model. <i>Oncology Letters</i> , 2016, 11, 2919-2924.	0.8	26
265	Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e163.	1.3	26
266	Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 841-849.	1.9	25
267	Safety evaluation of telbivudine. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 821-829.	1.0	25
268	Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. <i>Current Hepatitis Reports</i> , 2011, 10, 235-243.	0.3	25
269	Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. <i>Gut</i> , 2022, 71, 789-797.	6.1	25
270	Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. <i>Journal of Hepatology</i> , 2022, 77, 967-977.	1.8	25

#	ARTICLE	IF	CITATIONS
271	Hepatitis B Genotypes in Chronic Hepatitis B and Lamivudine Therapy. <i>Intervirolgy</i> , 2003, 46, 373-376.	1.2	24
272	Combination Therapy for Chronic Hepatitis B: Simultaneous or Sequential?. <i>American Journal of Gastroenterology</i> , 2007, 102, 105-106.	0.2	24
273	Etiologies of chronic liver diseases in Hong Kong. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 659-664.	0.8	24
274	The natural history of chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2007, 14, 6-10.	1.0	24
275	Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1063-1067.	1.9	24
276	Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. <i>Journal of Viral Hepatitis</i> , 2013, 20, 470-477.	1.0	24
277	Development of predisposition, injury, response, organ failure model for predicting acute kidney injury in acute on chronic liver failure. <i>Liver International</i> , 2017, 37, 1497-1507.	1.9	24
278	Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. <i>Hepatology International</i> , 2021, 15, 901-911.	1.9	24
279	Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2021, 74, 1795-1808.	3.6	24
280	Therapeutic vaccine BR11-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study. <i>JHEP Reports</i> , 2021, 3, 100361.	2.6	24
281	IRE1 α inhibition by natural compound genipin on tumour associated macrophages reduces growth of hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 43792-43804.	0.8	24
282	Hepatic necroinflammation and fibrosis in patients with genotypes Ba and C, core-promoter and precore mutations. <i>Journal of Viral Hepatitis</i> , 2005, 12, 513-518.	1.0	23
283	New paradigms for the treatment of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1182-1192.	1.4	23
284	Differential Reductions in Viral Antigens Expressed from CCCDNA Integrated DNA in Treatment Na ⁺ -ve HBEAG Positive and Negative Patients with Chronic HBV after RNA Interference Therapy with ARC-520. <i>Journal of Hepatology</i> , 2016, 64, S390-S391.	1.8	23
285	Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e100.	1.3	23
286	LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, e130.	1.8	23
287	HBsAg Seroclearance in Chinese Patients Receiving Lamivudine Therapy for Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4882-4884.	1.8	22
288	LB80380: a promising new drug for the treatment of chronic hepatitis B. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1581-1588.	1.9	22

#	ARTICLE	IF	CITATIONS
289	Quality of Life and Psychological Impact in Patients With Noncardiac Chest Pain. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 13-18.	1.1	22
290	Berberine Inhibition of Fibrogenesis in a Rat Model of Liver Fibrosis and in Hepatic Stellate Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-11.	0.5	22
291	DNA polymerase inhibitors for treating hepatitis B: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 383-392.	1.0	22
292	Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1473-1480.	1.0	22
293	Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. <i>Antiviral Therapy</i> , 2003, 8, 531-4.	0.6	22
294	Detection of Intrahepatic Hepatitis B Virus DNA and Correlation with Hepatic Necroinflammation and Fibrosis. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3920-3924.	1.8	21
295	Adefovir dipivoxil in chronic hepatitis B infection. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 2361-2367.	0.9	21
296	Pharmacokinetics of LB80331 and LB80317 following Oral Administration of LB80380, a New Antiviral Agent for Chronic Hepatitis B (CHB), in Healthy Adult Subjects, CHB Patients, and Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1779-1785.	1.4	21
297	Outcomes including liver histology after liver transplantation for chronic hepatitis B using oral antiviral therapy alone. <i>Liver Transplantation</i> , 2015, 21, 1504-1510.	1.3	21
298	Magnetic resonance cholangiogram patterns and clinical profiles of ketamine-related cholangiopathy in drug users. <i>Journal of Hepatology</i> , 2018, 69, 121-128.	1.8	21
299	ALT Levels for Asians With Metabolic Diseases: A Meta-analysis of 86 Studies With Individual Patient Data Validation. <i>Hepatology Communications</i> , 2020, 4, 1624-1636.	2.0	21
300	Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy. <i>Hepatology International</i> , 2022, 16, 211-253.	1.9	21
301	Significance of Viral Load, Core Promoter/Precore Mutations and Specific Sequences of Polymerase Gene in Hbv-Infected Patients on 3-Year Lamivudine Treatment. <i>Antiviral Therapy</i> , 2006, 11, 779-786.	0.6	21
302	Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2022, 77, 1265-1275.	1.8	21
303	Expression of Inhibitory Receptors in Natural Killer (CD3 ⁺ CD56 ⁺) Cells and CD3 ⁺ CD56 ⁺ Cells in the Peripheral Blood Lymphocytes and Tumor Infiltrating Lymphocytes in Patients with Primary Hepatocellular Carcinoma. <i>Clinical Immunology</i> , 2001, 101, 264-269.	1.4	20
304	Inhibition of Akt/PKB by a COX-2 Inhibitor Induces Apoptosis in Gastric Cancer Cells. <i>Digestion</i> , 2006, 73, 75-83.	1.2	20
305	Entecavir treatment in kidney transplant recipients infected with hepatitis B. <i>Clinical Transplantation</i> , 2014, 28, 1010-1015.	0.8	20
306	Relation of Tricuspid Regurgitation to Liver Stiffness Measured by Transient Elastography in Patients With Left-Sided Cardiac Valve Disease. <i>American Journal of Cardiology</i> , 2016, 117, 640-646.	0.7	20

#	ARTICLE	IF	CITATIONS
307	A Double-blind, Randomized Phase 2 Controlled Trial of Intradermal Hepatitis B Vaccination With a Topical Toll-like Receptor 7 Agonist Imiquimod, in Patients on Dialysis. <i>Clinical Infectious Diseases</i> , 2021, 73, e304-e311.	2.9	20
308	Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: Results of 24 weeks of therapy. <i>Journal of Medical Virology</i> , 2002, 67, 334-338.	2.5	19
309	Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 717-726.	2.0	19
310	Hepatitis B Surface Antigen Seroclearance: Relationship to Hepatitis B e-Antigen Seroclearance and Hepatitis B e-Antigen-Negative Hepatitis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1764-1770.	0.2	19
311	Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0148493.	1.1	19
312	Prevention and management of hepatitis B virus reactivation in cancer patients. <i>Hepatology International</i> , 2016, 10, 407-414.	1.9	19
313	Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection. <i>Viruses</i> , 2021, 13, 1169.	1.5	19
314	Outcome of Lamivudine-Resistant Chronic Hepatitis B after up to 5 Years of Combination Therapy with Adefovir. <i>Antiviral Therapy</i> , 2012, 17, 1255-1262.	0.6	18
315	New pharmacological approaches to a functional cure of hepatitis B. <i>Clinical Liver Disease</i> , 2016, 8, 83-88.	1.0	18
316	Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen. <i>Journal of Hepatology</i> , 2017, 66, S27.	1.8	18
317	Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis. <i>Digestive and Liver Disease</i> , 2017, 49, 202-206.	0.4	18
318	Hepatitis B virus (HBV) surface antigen (HBsAg) inhibition with isis 505358 in chronic hepatitis B (CHB) patients on stable nucleos (t)ide analogue (NA) regimen and in NA-naïve CHB patients: phase 2a, randomized, double-blind, placebo-controlled study. <i>Journal of Hepatology</i> , 2020, 73, S49-S50.	1.8	18
319	HBV X protein mutations affect HBV transcription and association of histone-modifying enzymes with covalently closed circular DNA. <i>Scientific Reports</i> , 2020, 10, 802.	1.6	18
320	Significance of Hepatitis B Virus Genotype in Liver Transplantation for Chronic Hepatitis B. <i>American Journal of Transplantation</i> , 2005, 5, 1893-1900.	2.6	17
321	Effectiveness of Chinese herbal medicine in treating liver fibrosis: a systematic review and meta-analysis of randomized controlled trials. <i>Chinese Medicine</i> , 2012, 7, 5.	1.6	17
322	The Role of Steatosis in HBsAg Seroclearance for Patients with Chronic Hepatitis B Infection: Fact or Fiction?. <i>Digestive Diseases and Sciences</i> , 2013, 58, 20-22.	1.1	17
323	The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , 2018, 38, 1179-1187.	1.9	17
324	Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2022, 77, 642-652.	1.8	17

#	ARTICLE	IF	CITATIONS
325	Effect of cyclo-oxygenase inhibitors on <i>Helicobacter pylori</i> susceptibility to metronidazole and clarithromycin. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 675-681.	1.9	16
326	Comparison of the COBAS TaqMan [®] , [†] HBV test with the COBAS Amplicor monitor [®] , [‡] test for measurement of hepatitis B virus DNA in serum. <i>Journal of Medical Virology</i> , 2005, 77, 486-490.	2.5	16
327	Colonoscopy Demand and Practice in a Regional Hospital over 9 Years in Hong Kong: Resource Implication for Cancer Screening. <i>Digestion</i> , 2006, 73, 84-88.	1.2	16
328	Chinese Medicines as an Adjuvant Therapy for Unresectable Hepatocellular Carcinoma during Transarterial Chemoembolization: A Meta-Analysis of Randomized Controlled Trials. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-25.	0.5	16
329	Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1230-1233.	1.4	16
330	A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance. <i>Journal of Viral Hepatitis</i> , 2020, 27, 397-406.	1.0	16
331	Management of chronic hepatitis B in severe liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 16053.	1.4	16
332	A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 977-83.	0.6	16
333	An evaluation of a rapid urine test for the diagnosis of <i>Helicobacter pylori</i> infection in the Chinese population. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 813-817.	1.9	15
334	Sequence Variations of Full-Length Hepatitis B Virus Genomes in Chinese Patients with HBsAg-Negative Hepatitis B Infection. <i>PLoS ONE</i> , 2014, 9, e99028.	1.1	15
335	Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. <i>Liver International</i> , 2018, 38, 1911-1919.	1.9	15
336	FRI-219-RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients. <i>Journal of Hepatology</i> , 2019, 70, e491.	1.8	15
337	Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00196.	1.3	15
338	Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study. <i>Journal of Hepatology</i> , 2020, 73, S140.	1.8	15
339	Tumor suppressive role of mitochondrial sirtuin 4 in induction of G2/M cell cycle arrest and apoptosis in hepatitis B virus-related hepatocellular carcinoma. <i>Cell Death Discovery</i> , 2021, 7, 88.	2.0	15
340	Cholangiocarcinoma in liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 337-341.	1.4	14
341	Long-Term Follow-Up Study of Chinese Patients with YMDD Mutations: Significance of Hepatitis B Virus Genotypes and Characteristics of Biochemical Flares. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3932-3936.	1.8	14
342	Outpatients undergoing therapeutic endoscopic retrograde cholangiopancreatography: Six-hour versus overnight observation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 1163-1168.	1.4	14

#	ARTICLE	IF	CITATIONS
343	Hepatitis B virus genotypes: natural history and implications for treatment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2007, 1, 321-328.	1.4	14
344	The use of transient elastography in the management of chronic hepatitis B. <i>Hepatology International</i> , 2011, 5, 868-875.	1.9	14
345	World Gastroenterology Organisation Global Guideline Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 691-703.	1.1	14
346	Deep sequencing analysis of quasispecies in the HBV pre-S region and its association with hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2017, 52, 1064-1074.	2.3	14
347	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 71-81.	1.9	14
348	Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2019, 25, 1398-1408.	1.4	14
349	Three-day lansoprazole quadruple therapy for <i>Helicobacter pylori</i> -positive duodenal ulcers: a randomized controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 843-849.	1.9	13
350	A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma. <i>Cancer</i> , 2003, 97, 2776-2782.	2.0	13
351	The Role of Cholecystectomy in Reducing Recurrent Gallstone Pancreatitis. <i>Endoscopy</i> , 2004, 36, 206-211.	1.0	13
352	A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. <i>Hepatology Research</i> , 2006, 35, 127-134.	1.8	13
353	The hepatitis B virus-associated estrogen receptor alpha (ER α) was regulated by microRNA-130a in HepG2.2.15 human hepatocellular carcinoma cells. <i>Acta Biochimica Et Biophysica Sinica</i> , 2011, 43, 640-646.	0.9	13
354	Evolutionary Changes of Hepatitis B Virus Pre-S Mutations Prior to Development of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0139478.	1.1	13
355	RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies. <i>Viruses</i> , 2021, 13, 581.	1.5	13
356	Expression of Fas antigen (CD95) in peripheral blood lymphocytes and in liver-infiltrating, cytotoxic lymphocytes in patients with hepatocellular carcinoma. <i>Cancer</i> , 2001, 92, 2136-2141.	2.0	12
357	The accuracy of SM-HCV rapid test for the detection of antibody to hepatitis C virus. <i>American Journal of Gastroenterology</i> , 2001, 96, 838-841.	0.2	12
358	One-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of <i>Helicobacter pylori</i> infection in Chinese. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 2067-2072.	1.9	12
359	Clinical Evaluation of the Digene Hybrid Capture II Test and the COBAS AMPLICOR Monitor Test for Determination of Hepatitis B Virus DNA Levels. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3513-3517.	1.8	12
360	Stability of E-cadherin methylation status in gastric mucosa associated with histology changes. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 831-836.	1.9	12

#	ARTICLE	IF	CITATIONS
361	Symptom Resolution Does Not Predict Healing of Erosive Oesophagitis in Chinese. <i>Digestion</i> , 2007, 75, 128-134.	1.2	12
362	Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B. <i>Journal of Infection</i> , 2007, 54, 497-503.	1.7	12
363	Mutational analysis for Wilson's disease. <i>Lancet, The</i> , 2009, 374, 662.	6.3	12
364	Profile of pre- ϵ S deletions in the natural history of chronic hepatitis B infection. <i>Journal of Medical Virology</i> , 2010, 82, 1843-1849.	2.5	12
365	Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: Outcome at 2 Years. <i>Hepatology</i> , 2011, 53, 1148-1153.	3.6	12
366	Application of Coamplification at Lower Denaturation Temperature-PCR Sequencing for Early Detection of Antiviral Drug Resistance Mutations of Hepatitis B Virus. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3209-3215.	1.8	12
367	HBV research moves forward—receptors and reactivation. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 70-72.	8.2	12
368	Anti-viral therapy in hepatitis B virus reactivation with acute-on-chronic liver failure. <i>Hepatology International</i> , 2015, 9, 373-377.	1.9	12
369	Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 789.	1.1	12
370	Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. <i>Hepatology International</i> , 2019, 13, 148-156.	1.9	12
371	Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1817-1823.	1.4	12
372	A Prospective Comparison of Performance of Biopsy Forceps Used in Single Passage with Multiple Bites During Upper Endoscopy. <i>Endoscopy</i> , 2003, 35, 338-342.	1.0	11
373	Systemic corticosteroid and reactivation of chronic hepatitis B. <i>Respirology</i> , 2010, 15, 1017-1018.	1.3	11
374	Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. <i>Hepatology International</i> , 2013, 7, 119-126.	1.9	11
375	Hepatitis B: treatment choice and monitoring for response and resistance. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 697-707.	1.4	11
376	Soluble fibrinogen-like protein 2 promotes the growth of hepatocellular carcinoma via attenuating dendritic cell-mediated cytotoxic T cell activity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 351.	3.5	11
377	Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue. <i>Liver International</i> , 2019, 39, 1217-1225.	1.9	11
378	First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients. <i>BMC Gastroenterology</i> , 2021, 21, 123.	0.8	11

#	ARTICLE	IF	CITATIONS
379	“First week”™ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure. <i>Hepatology International</i> , 2021, 15, 1376-1388.	1.9	11
380	Role of cholecystectomy in preventing recurrent cholangitis. <i>Gastrointestinal Endoscopy</i> , 2002, 56, 55-60.	0.5	10
381	Evaluation of two stool antigen tests for the detection of <i>Helicobacter pylori</i> infection in the Chinese population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 26-31.	1.4	10
382	Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection. <i>Current Hepatitis Reports</i> , 2011, 10, 106-111.	0.3	10
383	Effect of Hepatitis B Virus Reverse Transcriptase Variations on Entecavir Treatment Response. <i>Journal of Infectious Diseases</i> , 2014, 210, 701-707.	1.9	10
384	Hepatitis B virus full-length genomic mutations and quasispecies in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1638-1645.	1.4	10
385	Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000119.	1.1	10
386	Need to improve awareness and management of hepatitis B reactivation in patients receiving immunosuppressive therapy. <i>Hepatology International</i> , 2016, 10, 102-105.	1.9	10
387	Role of Core/Capsid Inhibitors in Functional Cure Strategies for Chronic Hepatitis B. <i>Current Hepatology Reports</i> , 2020, 19, 293-301.	0.4	10
388	Reversal of Protein-Losing Enteropathy by Liver Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, 86-87.	1.1	10
389	On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. <i>Liver International</i> , 2022, 42, 59-68.	1.9	10
390	Current and future antiviral agents for chronic hepatitis B. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 481-485.	1.3	9
391	Telbivudine: an upcoming agent for chronic hepatitis B. <i>Expert Review of Anti-Infective Therapy</i> , 2005, 3, 489-494.	2.0	9
392	Non-alcoholic fatty liver disease and risk of in-stent restenosis after bare metal stenting in native coronary arteries. <i>Molecular Biology Reports</i> , 2014, 41, 4713-4720.	1.0	9
393	Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance. <i>Liver International</i> , 2016, 36, 642-650.	1.9	9
394	Intrahepatic hepatitis B virus replication and liver histology in subjects with occult hepatitis B infection. <i>Clinical Microbiology and Infection</i> , 2016, 22, 290.e1-290.e3.	2.8	9
395	Expansion of Granulocytic, Myeloid-Derived Suppressor Cells in Response to Ethanol-Induced Acute Liver Damage. <i>Frontiers in Immunology</i> , 2018, 9, 1524.	2.2	9
396	Artificial Neural Network Accurately Predicts Hepatitis B Surface Antigen Seroclearance. <i>PLoS ONE</i> , 2014, 9, e99422.	1.1	9

#	ARTICLE	IF	CITATIONS
397	Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 553-564.	4.5	9
398	Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. <i>Antiviral Therapy</i> , 2009, 14, 679-685.	0.6	9
399	Tension pneumothorax complicating ERCP in a patient with a Billroth II gastrectomy. <i>Gastrointestinal Endoscopy</i> , 2001, 54, 254-256.	0.5	8
400	Impact of precore and core promoter mutations on hepatic histology in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 301-307.	1.9	8
401	'Immune tolerance' in HBV infection: danger lurks. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 627-628.	8.2	8
402	Emerging drugs for the treatment of hepatitis B. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 183-193.	1.0	8
403	An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 483-491.	1.5	8
404	RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV. <i>Journal of Hepatology</i> , 2018, 68, S526.	1.8	8
405	Model for End-Stage Liver Disease With Additional Criteria to Predict Short-Term Mortality in Severe Flares of Chronic Hepatitis B. <i>Hepatology</i> , 2020, 72, 818-828.	3.6	8
406	Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1315-1326.	1.1	8
407	Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 554-561.	4.5	8
408	Significance of viral load, core promoter/precure mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment. <i>Antiviral Therapy</i> , 2006, 11, 779-86.	0.6	8
409	Detection of the Hepatitis B Surface Antigen in Patients with Occult Hepatitis B by Use of an Assay with Enhanced Sensitivity. <i>Journal of Clinical Microbiology</i> , 2022, 60, jcm0220421.	1.8	8
410	Clonal Marrow Abnormalities after Azathioprine and Sulfasalazine Exposure in Crohn's Disease: A Cautionary Tale. <i>Leukemia and Lymphoma</i> , 2002, 43, 1679-1681.	0.6	7
411	Stability of hepatitis B surface antigen over time: Implications for studies using stored sera. <i>Journal of Medical Virology</i> , 2011, 83, 1900-1904.	2.5	7
412	Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. <i>Hepatology International</i> , 2012, 6, 696-706.	1.9	7
413	Monitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1410-1412.	2.4	7
414	Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes. <i>Endocrinology and Metabolism</i> , 2021, 36, 134-145.	1.3	7

#	ARTICLE	IF	CITATIONS
415	Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 7863-7874.	1.4	7
416	Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure. <i>Hepatology International</i> , 2022, 16, 171-182.	1.9	7
417	Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. <i>Hepatology International</i> , 2022, 16, 48-58.	1.9	7
418	JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2022, 27, 135965352210938.	0.6	7
419	Prevalence and characteristics of familial hepatocellular carcinoma caused by chronic hepatitis B infection in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 401-406.	1.9	6
420	Determinants for the Occurrence of Acute Exacerbation of Hepatitis B Virus Infection in Chinese Patients after HBeAg Seroclearance. <i>Journal of Clinical Microbiology</i> , 2005, 43, 1594-1599.	1.8	6
421	Hepatitis B surface antigen levels after hepatitis B e antigen seroclearance: a longitudinal follow-up study. <i>Liver International</i> , 2015, 35, 854-859.	1.9	6
422	Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation. <i>Transplantation</i> , 2017, 101, 2391-2398.	0.5	6
423	Future Therapies for Functional Cure of Chronic HBV: Review of Investigational Drugs in Phase 1 and 2 Development. <i>Current Hepatology Reports</i> , 2019, 18, 503-511.	0.4	6
424	Evaluation of a new referral system for the management of dyspepsia in Hong Kong: Role of open-access upper endoscopy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1251-1256.	1.4	6
425	Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2020, 14, 665-668.	1.4	6
426	Alleviation of Hepatic Steatosis: Dithizone-Related Gut Microbiome Restoration During Paneth Cell Dysfunction. <i>Frontiers in Microbiology</i> , 2022, 13, 813783.	1.5	6
427	A pilot study of participation in faecal occult blood testing and screening colonoscopy after health education in Hong Kong. <i>European Journal of Cancer Prevention</i> , 2005, 14, 181-184.	0.6	5
428	Effects of Aspirin on the Development of <i>Helicobacter pylori</i> -Induced Gastric Inflammation and Heterotopic Proliferative Glands in Mongolian Gerbils. <i>Helicobacter</i> , 2008, 13, 20-29.	1.6	5
429	A comprehensive HBV array for the detection of HBV mutants and genotype. <i>Clinical Biochemistry</i> , 2011, 44, 1253-1260.	0.8	5
430	Future Prevention and Treatment of Chronic Hepatitis B Infection. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 725-734.	1.1	5
431	Factors for Hepatitis B vaccination and Abnormal Liver Function in Chinese Patients with Inflammatory Bowel Disease: A Single Center Experience. <i>Journal of Digestive Diseases</i> , 2013, 14, n/a-n/a.	0.7	5
432	The role of interleukin-27 in predicting spontaneous HBeAg seroconversion in chronic hepatitis B infection. <i>Liver International</i> , 2017, 37, 1287-1294.	1.9	5

#	ARTICLE	IF	CITATIONS
433	Magnetic resonance elastography and proton density fat fraction predict adverse outcomes in hepatocellular carcinoma. <i>Hepatology International</i> , 2022, 16, 371-380.	1.9	5
434	Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 127-140.	1.0	5
435	New strategies for the treatment of chronic hepatitis B. <i>Trends in Molecular Medicine</i> , 2022, 28, 742-757.	3.5	5
436	<sc>HLA</sc> and <sc>DP</sc> and <sc>interferon receptor</sc> gene variants and their association with viral hepatitis activity in chronic hepatitis <sc>B</sc> infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 533-539.	1.4	4
437	Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 101-106.	1.5	4
438	A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants. <i>Clinical Therapeutics</i> , 2018, 40, 719-732.e1.	1.1	4
439	Trends in Liver Transplantation for Chronic Hepatitis B in an Era of Highly Potent Antiviral Therapies. <i>Liver Transplantation</i> , 2021, 27, 134-139.	1.3	4
440	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 874-885.e4.	2.4	4
441	A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS601-TPS601.	0.8	4
442	Quantitative hepatitis B surface antigen in predicting recurrence of hepatitis B-related hepatocellular carcinoma after liver transplantation. <i>Hepatoma Research</i> , 2018, 4, 62.	0.6	4
443	Measuring and Validating a General Cancer Predisposition Perception Scale: An Adaptation of the Revised-IPQ-Genetic Predisposition Scale. <i>PLoS ONE</i> , 2015, 10, e0142620.	1.1	4
444	Phenotypic Changes of PD-1 and GITR in T Cells Are Associated With Hepatitis B Surface Antigen Seroclearance. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, e31-e37.	1.1	4
445	Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. <i>Antiviral Therapy</i> , 2009, 14, 679-85.	0.6	4
446	Evaluation of a new referral system for the management of dyspepsia in Hong Kong: Role of open-access upper endoscopy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1251-1256.	1.4	3
447	Evaluation of a rapid stool antigen test for the diagnosis of <i>Helicobacter pylori</i> infection in Chinese patients. <i>Chinese Journal of Digestive Diseases</i> , 2003, 4, 132-135.	1.1	3
448	Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B results of a comparative study in 96 Chinese patients. <i>American Journal of Gastroenterology</i> , 2003, 98, 1181-1185.	0.2	3
449	Hepatitis C Virus Infection in Adult Chinese Hemophilia Patients Negative for the Human Immunodeficiency Virus: Treatment Results with Interferon and Ribavirin. <i>International Journal of Hematology</i> , 2005, 82, 259-261.	0.7	3
450	Prediction of treatment outcomes for lamivudine. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 964-965.	1.4	3

#	ARTICLE	IF	CITATIONS
451	Occult hepatitis B infection: Incidence, detection and clinical implications. <i>ISBT Science Series</i> , 2009, 4, 347-351.	1.1	3
452	Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B mono-infection. <i>Hepatology International</i> , 2013, 7, 327-334.	1.9	3
453	Relationship between hepatitis B core-related antigen and chronic hepatitis B outcome in HBeAg negative patients: a 10-year longitudinal study. <i>Journal of Hepatology</i> , 2018, 68, S478.	1.8	3
454	Plasma Fibronectin Levels Identified via Quantitative Proteomics Profiling Predicts Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2019, 220, 940-950.	1.9	3
455	Prognostic value and reversibility of liver stiffness in patients undergoing tricuspid annuloplasty. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 551-559.	0.5	3
456	Role of Serum M2BPGi Levels in Predicting Persistence of Advanced Fibrosis in Chronic Hepatitis B Virus Infection. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5127-5136.	1.1	3
457	Recombinant Interferon Alfa 2b Therapy in a Patient With Metastatic Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2002, 35, 272-275.	1.1	2
458	Specific Considerations in the Design of Hepatitis B Virus Clinical Studies in the Far East. , 2004, 96, 457-464.		2
459	Overcoming the problem of chronic hepatitis B. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006, 3, 197-202.	0.5	2
460	Factors Affecting Physicians' Practices Related to <i>Helicobacter pylori</i> Infection: Effect of Experience and Mode of Practice. <i>Digestion</i> , 2008, 78, 77-81.	1.2	2
461	Telbivudine for chronic hepatitis B: the GLOBE trial. <i>Future Virology</i> , 2008, 3, 317-323.	0.9	2
462	The saga of entecavir. <i>Hepatology International</i> , 2009, 3, 421-424.	1.9	2
463	To stop or not to stop: The quest for long-term viral suppression. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 420-422.	1.4	2
464	Management of Chronic Hepatitis B in Patients from Special Populations. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021527-a021527.	2.9	2
465	Clinical implication of occult hepatitis B infection. <i>Annals of Blood</i> , 0, 2, 5-5.	0.4	2
466	Hepatitis B Virus: Asian Perspective. , 2019, , 99-116.		2
467	Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance. <i>Hepatology International</i> , 2021, 15, 881-891.	1.9	2
468	Biological Gradient of Chronic Hepatitis B. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 593-593.	8.2	2

#	ARTICLE	IF	CITATIONS
469	Development and validation of a therapy-independent hepatocellular carcinoma survival prediction score. <i>Liver Cancer International</i> , 0, , .	0.2	2
470	Magnetic resonance imaging metrics and the predictability of adverse outcomes in on-treatment Asian chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, , .	1.4	2
471	Prevalence and significance of hepatitis GB virus-c/hepatitis G virus viremia in a large cohort of patients with chronic hepatitis B infection, with chronic hepatitis C infection, and on renal replacement therapy in Hong Kong. <i>Digestive Diseases and Sciences</i> , 2002, 47, 432-437.	1.1	1
472	Treatment for Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, S134-S135.	1.1	1
473	What Is the Best End Point for Hepatitis B Treatment?. <i>Annals of Internal Medicine</i> , 2008, 148, 560.	2.0	1
474	Nucleic Acid Testing for the Detection of HBV DNA. <i>Hepatitis Monthly</i> , 2011, 11, 847-848.	0.1	1
475	Reply to Liao et al. <i>Clinical Infectious Diseases</i> , 2013, 57, 622-622.	2.9	1
476	Reply:. <i>Hepatology</i> , 2013, 58, 1857-1857.	3.6	1
477	A territory-wide study on the seroprevalence of hepatitis B and C virus in the general population in Hong Kong, China. <i>Journal of Hepatology</i> , 2017, 66, S682.	1.8	1
478	Should red blood cell transfusion be immediately given to a cirrhotic patient with active upper gastrointestinal bleeding?. <i>AME Medical Journal</i> , 0, 3, 83-83.	0.4	1
479	Letter: serum <sc>HB</sc>crAg is a useful marker for disease monitoring, predicting treatment response and disease outcome of chronic hepatitis B virus infectionâauthors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1720-1721.	1.9	1
480	In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3630-3641.	1.1	1
481	Clonal expansion of hepatocytes and state of hepatitis B virus DNA integration in patients with nucleos(t)ide analogue therapy. <i>Journal of Hepatology</i> , 2020, 73, S602-S603.	1.8	1
482	Reply. <i>Hepatology</i> , 2022, 75, 1050-1051.	3.6	1
483	Nucleic Acid Testing for the Detection of HBV DNA. <i>Hepatitis Monthly</i> , 2011, 11, 847-848.	0.1	1
484	Enhanced Liver Fibrosis Score Stratifies Hepatocellular Carcinoma Risk in Patients With Hepatitis B Surface Antigen Seroclearance. <i>Clinical Infectious Diseases</i> , 2022, 75, 2257-2259.	2.9	1
485	Entecavir. <i>Drugs</i> , 2006, 66, 1623-1624.	4.9	0
486	Recommendations and potential future options in the treatment of hepatitis B. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 2225-2231.	0.9	0

#	ARTICLE	IF	CITATIONS
487	New Exploration of Chinese Herbal Medicines in Hepatology. Evidence-based Complementary and Alternative Medicine, 2016, 2016, 1-5.	0.5	0
488	Letter: is body mass index really associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B? Authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 483-483.	1.9	0
489	Response to Toyoda et al.. American Journal of Gastroenterology, 2017, 112, 970.	0.2	0
490	Risk Factors for Graft Steatosis after Liver Transplantation using Controlled Attenuation Parameter Measurements. Transplantation, 2018, 102, S863.	0.5	0
491	Reply. Clinical Gastroenterology and Hepatology, 2021, 19, 408-409.	2.4	0
492	REPLY:. Hepatology, 2021, 74, 533-534.	3.6	0
493	Novel Therapy for Functional Cure of Chronic Hepatitis B Virus Infection. , 2021, , 455-473.		0
494	Acute Hepatitis as a Presentation of Acute Appendicitis in an Immunocompromised Patient. Journal of Clinical Gastroenterology, 2002, 35, 203-204.	1.1	0
495	Clinical experience and follow-up with lamivudine in the Asian population. , 2003, , 383-390.		0
496	New Antiviral Treatment for Chronic Hepatitis B. , 2004, , 47-56.		0
497	Occult Hepatitis B Infection. , 2018, , 297-313.		0
498	Do statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B?. Hepatobiliary Surgery and Nutrition, 2013, 2, 34-6.	0.7	0